Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06890598 · ClinicalTrials.gov registry record · Phase 3

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

A Phase 3 study of Carcinoma, Non-Small Cell Lung, sponsored by Eli Lilly and Company.

Recruiting
Registry status
Phase 3
Development phase
700
Enrollment target
20
Study locations

NCT06890598: Recruiting Phase 3 study of Carcinoma, Non-Small Cell Lung, sponsored by Eli Lilly and Company.

NCT06890598 is a Phase 3 study of Carcinoma, Non-Small Cell Lung that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 700 participants, above the 318-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (120% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06890598, a Phase 3 study of Carcinoma, Non-Small Cell Lung, is actively recruiting participants, sponsored by Eli Lilly and Company.

RECRUITING
Registry status
Phase 3
Development phase
700 participants
Enrollment target
20
Study locations

Study Summary

The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if olomorasib in combination with durvalumab is more effective than the durvalumab and placebo combination in part B in participants with unresectable KRAS G12C-mutant non-small cell lung cancer. The study may last up to 3 years for each participant.

Primary Outcome

DFS by Investigator Assessment

Conditions Studied

Carcinoma, Non-Small Cell Lung

Interventions

  • DRUG Pembrolizumab
  • DRUG Placebo
  • DRUG Durvalumab
  • DRUG Olomorasib

Study Locations (20)

Florida

  • Boca Raton Regional Hospital - Boca Raton
  • Florida Cancer Specialists - South - Fort Myers
  • University of Florida - Jacksonville - Jacksonville
  • Miami Cancer Institute at Baptist Health, Inc. - Miami
  • Florida Cancer Specialists North - St. Petersburg
  • Comprehensive Hematology Oncology - St. Petersburg
  • Moffitt Cancer Center - Tampa
  • Florida Cancer Specialists East - West Palm Beach

California

  • UCLA Hematology/Oncology - Santa Monica - Los Angeles
  • Profound Research LLC - Oceanside
  • University of California, Irvine (UCI) Health - UC Irvine Medical Center - Orange
  • Stanford Cancer Center - Palo Alto
  • Kaiser Permanente San Diego Mission Road - San Diego
  • BASS Cancer Center - Walnut Creek

Alabama

  • Clearview Cancer Institute - Huntsville
  • Infirmary Cancer Care - Mobile

Arizona

  • The University of Arizona Cancer Center - North Campus - Tucson

Arkansas

  • Highlands Oncology Group - Springdale

Connecticut

  • Hartford Hospital (HH) - Hartford

District of Columbia

  • Sibley Memorial Hospital - Washington D.C.

Trial Details

FieldValue
Enrollment Target 700 participants
Start Date 2025-03-27
Est. Completion 2032-02
Phase Phase 3
Eli Lilly and Company

1,341 total trials

What NCT06890598 shows while recruiting

NCT06890598 is an interventional study that assigns participants to a tested intervention. The registered 700 participants enrollment target is mid-sized for trials with a published cap, above the 318-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (120% higher).

The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.

NCT06890598 names 20 study sites across 7 states, led by Florida, California, Alabama.

Frequently Asked Questions

What is clinical trial NCT06890598 about?

NCT06890598 is a clinical study titled "Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer". The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if olomorasib in combination with durvalumab is more effective tha...

What is the current status of trial NCT06890598?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 700 participants. The study started on 2025-03-27. Estimated completion is 2032-02.

What conditions does trial NCT06890598 study?

This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.

What interventions are being tested in trial NCT06890598?

The interventions under investigation include: Pembrolizumab (DRUG), Placebo (DRUG), Durvalumab (DRUG), Olomorasib (DRUG).

Who is sponsoring clinical trial NCT06890598?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06890598 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Non-Small Cell Lung

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06890598's enrollment target sits among peer trials

700 20th of 130 higher than 111 of 130 other Carcinoma, Non-Small Cell Lung trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Carcinoma, Non-Small Cell Lung trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00900419 · 700 participants

    Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers

  • NCT01804686 · 700 participants · Phase 3

    A Long-term Extension Study of PCI-32765 (Ibrutinib)

  • NCT02107989 · 700 participants

    Noninvasive Pre-surgical Evaluation of Patients With Focal Epilepsy and Establishment of a Normative Imaging Database

  • NCT02129543 · 700 participants

    Immune Reconstitution in Stem Cell Transplant Recipients

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06890598

Source: ClinicalTrials.gov NCT06890598, the US trial registry maintained by the National Library of Medicine. NCT06890598 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.